Vafidemstat for Borderline Personality Disorder
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called vafidemstat to see if it can help adults with borderline personality disorder. The study will check if the medication is safe and effective over several weeks.
Will I have to stop taking my current medications?
The trial requires that you maintain your current medication regimen throughout the study and not start any new prohibited medications. You should inform your study physician of any changes in your medications during the trial.
What data supports the effectiveness of the drug Vafidemstat for treating Borderline Personality Disorder?
How does the drug Vafidemstat differ from other treatments for borderline personality disorder?
Vafidemstat is unique because it is being specifically studied for its effects on borderline personality disorder, whereas other treatments like antipsychotics, antidepressants, and mood stabilizers are often used based on their effects on related symptoms rather than the disorder itself. This trial is exploring its potential as a novel option, distinct from existing medications that target symptoms like mood instability and impulsivity.12367
Research Team
Michael Ropacki, MD
Principal Investigator
Oryzon Genomics
Eligibility Criteria
This trial is for adults aged 18-65 with Borderline Personality Disorder (BPD), confirmed by specific criteria and interviews. Participants should have a BMI between 18.5 and 35, indicating a healthy weight range. Those who've attempted suicide or taken esketamine in the past three months cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive vafidemstat or placebo for 14 weeks in a double-blind, randomized, placebo-controlled setting
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo
- Vafidemstat
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oryzon Genomics S.A.
Lead Sponsor